38136-96-8

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine is used as a key intermediate in the synthesis of new drugs, particularly for the development of therapeutic agents targeting various diseases. Its unique chemical structure allows for the creation of novel compounds with potential medicinal properties.
Used in Agrochemical Industry:
In the agrochemical sector, 6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine serves as a precursor in the production of innovative pesticides. Its incorporation into these formulations can lead to the development of more effective and targeted pest control solutions.
Used in Organic Synthesis:
6-Chloro-2-(methylthio)-5-nitropyrimidin-4-amine is utilized as a building block in organic synthesis, enabling the construction of complex molecules with diverse applications across various fields. Its versatile structure facilitates the creation of new chemical entities with tailored properties for specific uses.

Upstream product

• 127726-91-4 6-amino-2-methylthio-5-nitropyrimidin-4-ol 
• 1979-96-0 4,6-dichloro-2-(methylthio)-5-nitropyrimidine 
• 1979-97-1 2-(methylthio)-5-nitropyrimidine-4,6-diol 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 

Downstream Products

• 949109-51-7 4-amino-2-methylthio-5-nitro-6-phenylethynylpyrimidine 
• 949109-52-8 4-amino-2-methylthio-7-oxo-6-phenyl-7H-pyrrolo[3,2-d]pyrimidine-5-oxide 
• 1228587-56-1 ethyl 2-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)acetate 
• 1228587-60-7 methyl 1-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-(pyrrolidin-1-ylmethyl)benzyl)amino)cyclopropanecarboxylate 
• 1228588-11-1 ethyl 2-((6-amino-2-(methylthio)-5-nitropyrimidin-4-yl)(3-cyanobenzyl)amino)acetate 
• 1228588-20-2 ethyl-Nβ-[4-amino-2-methylthio-5-nitropyrimidin-6-yl],Nβ-[3′-(pyrrolidin-1″-ylmethyl)-benzyl]-β-alaninoate 
• 1228588-84-8 C₂₃H₃₀N₆O₆S 
• 1434589-63-5 C₁₇H₁₇ClN₄O₆S 
• 1434589-67-9 C₁₇H₁₉N₅O₆S 
• 1434589-71-5 C₁₇H₁₉N₅O₈S 
• 1228588-18-8 ethyl-Nα-[4-amino-2-methanesulfonyl-5-nitropyrimidin-6-yl],Nα-[3'-(pyrrolidin-1-ylmethyl)-benzyl]-glycinate 
• 1228587-65-2 ethyl 2-((6-amino-2-(methylsulfonyl)-5-nitropyrimidin-4-yl)(4-(pyrrolidin-1-ylmethyl)benzyl)amino)acetate 
• 1539303-96-2 C₁₈H₂₁N₅O₆S 
• 1539303-99-5 ethyl (6-chloro-2-(methylthio)-5-nitropyrimidin-4-yl)(3-methoxybenzyl)carbamate 

Relevant academic research and scientific papers

Potent and Selective Inhibitors of MTH1 Probe Its Role in Cancer Cell Survival

Recent literature has claimed that inhibition of the enzyme MTH1 can eradicate cancer. MTH1 is one of the housekeeping enzymes that are responsible for hydrolyzing damaged nucleotides in cells and thus prevent them from being incorporated into DNA. We have developed orthogonal and chemically distinct tool compounds to those published in the literature to allow us to test the hypothesis that inhibition of MTH1 has wide applicability in the treatment of cancer. Here we present the work that led to the discovery of three structurally different series of MTH1 inhibitors with excellent potency, selectivity, and proven target engagement in cells. None of these compounds elicited the reported cellular phenotype, and additional siRNA and CRISPR experiments further support these observations. Critically, the difference between the responses of our highly selective inhibitors and published tool compounds suggests that the effect reported for the latter may be due to off-target cytotoxic effects. As a result, we conclude that the role of MTH1 in carcinogenesis and utility of its inhibition is yet to be established.

MACROCYCLIC PURINES FOR THE TREATMENT OF VIRAL INFECTIONS

This invention relates macrocyclic purine derivatives having formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS

The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

Identification and optimization of pteridinone toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis

Pteridinone-based Toll-like receptor 7 (TLR7) agonists were identified as potent and selective alternatives to the previously reported adenine-based agonists, leading to the discovery of GS-9620. Analogues were optimized for the immunomodulatory activity and selectivity versus other TLRs, based on differential induction of key cytokines including interferon α (IFN-α) and tumor necrosis factor α (TNF-α). In addition, physicochemical properties were adjusted to achieve desirable in vivo pharmacokinetic and pharmacodynamic properties. GS-9620 is currently in clinical evaluation for the treatment of chronic hepatitis B (HBV) infection.

METHODS FOR TREATING HCV

This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.

MODULATORS OF TOLL-LIKE RECEPTORS

Provided are modulators of TLRs of Formula II: pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

The Synthesis and Chlorination of Some Pyrimidin-4-ols Having 5-Nitrogen Functionality

Syntheses of a number of pyrimidin-4-ols having 5-nitrogen functionality are described.Phosphorus oxychloride/diethylaniline chlorination of 6-amino-2-methylthio-5-nitropyrimidin-4-ol gave the corresponding 6-chloro derivative.However, 2-amino-6-methylthi